Eigen Bio AI
June 25, 2026
Theater 2
Type: Company Presentation
Focus Area:
AI and Digital Health
Eigen Bio is a frontier wet AI lab. We integrate biology, AI, and causal inference to build a platform that reads gene regulation directly from blood and predicts how it changes under therapeutic intervention. Our foundation model, Eigen-1, is trained on plasma-derived RNA and large-scale perturbation data in human cells, giving it a mechanistic view of disease that drives earlier, more confident decisions in drug development.
Company HQ City:
New York
Company HQ State:
NY
Company HQ Country:
United States
Year Founded:
2025
Lead Product in Development:
Eigen-1 — a foundation model trained on plasma-derived RNA from extracellular vesicles and large-scale perturbation data in human cells, enabling mechanistic prediction of how biology responds to therapeutic intervention
CEO
Sang Lee
Development Phase of Lead Product
Other/Not Applicable
Number of Unlicensed Products Looking for Licensing
n/a
When you expect your next catalyst update?
H2 2026
Primary Speaker
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}